THERAPY DOSSIER · th-cab6ed55b55f

Recombinant human neuritin protein expressed in and purified from Pichia pastoris

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27009445 ↗2016Reported benefit

Exogenous Neuritin Promotes Nerve Regeneration After Acute Spinal Cord Injury in Rats.

RatSpinal cord injuryUnspecifiedWistarMale and female60 micrograms/mLEarly stage after spinal cord injury

Model: Acute spinal cord injury

A recombinant neuritin concentration of 60 micrograms/mL induced recovery of hind limb motor function and stimulated nerve regeneration. Continuous administration at this dose early after injury inhibited PARP protein degradation and decreased neuronal apoptosis, and during the critical period of a…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…